Argenx Files for FDA Approval of Efgartigimod for Generalized MG

Argenx Files for FDA Approval of Efgartigimod for Generalized MG

282641

Argenx Files for FDA Approval of Efgartigimod for Generalized MG

Argenx has filed an application to the U.S. Food and Drug Administration (FDA) requesting the approval of efgartigimod (ARGX-113) to treat generalized myasthenia gravis (gMG). Similar approval requests are on track to be filed in Europe and Japan this year, Argenx stated in a recently released corporate update. A filing with Chinese regulatory authorities is also planned, likely come soon after the FDA’s decision is announced. In preparation for efgartigimod’s possible approval and commercialization in the U.S., Argenx is…

You must be logged in to read/download the full post.